Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer AA Khorana, GA Soff, AK Kakkar, S Vadhan-Raj, H Riess, T Wun, ... New England Journal of Medicine 380 (8), 720-728, 2019 | 727 | 2019 |
Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology J Neuberger, J Patel, H Caldwell, S Davies, V Hebditch, C Hollywood, ... Gut 69 (8), 1382-1403, 2020 | 335 | 2020 |
Inflammatory biomarkers in Alzheimer's disease plasma AR Morgan, S Touchard, C Leckey, C O'Hagan, AJ Nevado-Holgado, ... Alzheimer's & dementia 15 (6), 776-787, 2019 | 165 | 2019 |
Cost effectiveness of pharmacogenetic testing for drugs with clinical pharmacogenetics implementation consortium (CPIC) guidelines: a systematic review SA Morris, AT Alsaidi, A Verbyla, A Cruz, C Macfarlane, J Bauer, JN Patel Clinical Pharmacology & Therapeutics 112 (6), 1318-1328, 2022 | 96 | 2022 |
Clinical implementation of germ line cancer pharmacogenetic variants during the next‐generation sequencing era NK Gillis, JN Patel, F Innocenti Clinical Pharmacology & Therapeutics 95 (3), 269-280, 2014 | 73 | 2014 |
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer JN Patel, I Braicu, KM Timms, C Solimeno, P Tshiaba, J Reid, ... British journal of cancer 119 (9), 1060-1066, 2018 | 63 | 2018 |
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy DL Hertz, K Owzar, S Lessans, C Wing, C Jiang, WK Kelly, J Patel, ... Clinical Cancer Research 22 (19), 4890-4900, 2016 | 58 | 2016 |
Acupuncture for cancer pain and symptom management in a palliative medicine clinic KR Miller, JN Patel, JT Symanowski, CA Edelen, D Walsh American Journal of Hospice and Palliative Medicine® 36 (4), 326-332, 2019 | 57 | 2019 |
Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives JN Patel Pharmacogenomics and personalized medicine, 65-77, 2016 | 55 | 2016 |
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer GR Williams, AM Deal, SS Shachar, CM Walko, JN Patel, B O’Neil, ... Cancer chemotherapy and pharmacology 81, 413-417, 2018 | 54 | 2018 |
Colorectal cancer biomarkers in the era of personalized medicine JN Patel, MK Fong, M Jagosky Journal of personalized medicine 9 (1), 3, 2019 | 52 | 2019 |
A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy JN Patel, BH O'Neil, AM Deal, JG Ibrahim, GB Sherrill, OA Olajide, ... The oncologist 19 (9), 959-965, 2014 | 48 | 2014 |
Personalizing aromatase inhibitor therapy in patients with breast cancer IS Hamadeh, JN Patel, S Rusin, AR Tan Cancer treatment reviews 70, 47-55, 2018 | 44 | 2018 |
Value of supportive care pharmacogenomics in oncology practice JN Patel, LA Wiebe, HM Dunnenberger, HL McLeod The Oncologist 23 (8), 956-964, 2018 | 39 | 2018 |
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration‐resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB … JN Patel, C Jiang, DL Hertz, FA Mulkey, K Owzar, S Halabi, MJ Ratain, ... Cancer 121 (7), 1025-1031, 2015 | 38 | 2015 |
Cancer pharmacogenomics: implications on ethnic diversity and drug response JN Patel Pharmacogenetics and Genomics 25 (5), 223-230, 2015 | 37 | 2015 |
Lung cancer biomarkers, targeted therapies and clinical assays JN Patel, JL Ersek, ES Kim Translational lung cancer research 4 (5), 503, 2015 | 35 | 2015 |
HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line … KR Miller, JN Patel, Q Zhang, EJ Norris, J Symanowski, C Michener, ... Gynecologic Oncology 149 (1), 155-162, 2018 | 34 | 2018 |
Comparison of FDA table of pharmacogenetic associations and clinical pharmacogenetics implementation consortium guidelines D Pritchard, JN Patel, LE Stephens, HL McLeod American Journal of Health-System Pharmacy 79 (12), 993-1005, 2022 | 33 | 2022 |
Evaluation of CYP 2C19 Genotype‐Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant JN Patel, IS Hamadeh, M Robinson, Z Shahid, J Symanowski, ... Clinical Pharmacology & Therapeutics 107 (3), 571-579, 2020 | 33 | 2020 |